

Abemaciclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast

Abiraterone

Section	Indications
Hormones and antihormones Oral > Solid: 250 mg; 500 mg	Malignant neoplasms of prostate

Afatinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

All-trans retinoic acid

Section	Indications
Targeted therapies Oral > Solid: 10 mg capsule	Acute myeloid leukaemia with recurrent genetic abnormalities

Allopurinol

Section	Indications
Supportive medicines - Parenteral > General injections > IV: 500 mg (as sodium) powder for injection - Oral > Solid: 100 mg; 300 mg	Tumour lysis syndrome

Anastrozole

Section	Indications
Hormones and antihormones Oral > Solid: 1 mg tablet	Other specified malignant neoplasms of breast Malignant neoplasms of breast

Arsenic trioxide

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Asparaginase

Section

Cytotoxic medicines

- Powder for injection: 10 000 IU in vial.
- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Atezolizumab

Section

Immunomodulators

- Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
- Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

Indications

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to [pembrolizumab](#) for

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to [pembrolizumab](#) for

Adenocarcinoma of stomach

Hepatocellular carcinoma of liver

Axicabtagene ciloleucel

Section

Antineoplastics and supportive medicines

- Cell suspension for infusion: 2×10^6 anti-CD19 CAR-positive viable T-cells per kg of body weight.

Indications

Diffuse large B-cell lymphomas

Axitinib

Section

Targeted therapies

- Oral > Solid > tablet: 1 mg; 3 mg; 5 mg

Indications

Renal cell carcinoma of kidney, except renal pelvis

Azacitidine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection

Indications

Myeloid leukaemia

Bendamustine

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Follicular lymphoma

Bevacizumab

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

Indications

Hepatocellular carcinoma of liver

Bicalutamide

Section

Hormones and antihormones

- Oral > Solid: 50 mg

Indications

Malignant neoplasms of prostate

Binimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to [trametinib](#) for

Other specified melanoma of skin

Bleomycin

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)

Indications

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Unspecified malignant neoplasms of ill-defined or unspecified sites

Blinatumomab

Section

Immunomodulators

- Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial

Indications

B lymphoblastic leukaemia or lymphoma, not elsewhere classified

Bortezomib

Section

Targeted therapies

- Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

Indications

Plasma cell myeloma

Calcium folinate (leucovorin calcium)

Section

Cytotoxic medicines

- Oral > Solid: 15 mg tablet
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasm metastasis in large intestine

Burkitt lymphoma including Burkitt leukaemia

Malignant trophoblastic neoplasms of placenta

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of rectum

Malignant neoplasms of colon

Capecitabine

Section

Cytotoxic medicines

- Oral > Solid > tablet: 150 mg; 500 mg

Indications

Other specified malignant neoplasms of breast

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

Malignant neoplasms of colon

Carboplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL	- Other specified malignant neoplasms of bronchus or lung - Other specified gliomas of brain - Malignant neoplasms of nasopharynx - Malignant neoplasms of breast - Osteosarcoma of bone and articular cartilage of unspecified sites - Other specified carcinomas of ovary - Retinoblastoma - Other specified malignant neoplasms of the ovary - Germ cell tumour of testis - Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx - Malignant neoplasms of kidney, except renal pelvis - Malignant neoplasms of cervix uteri - Malignant neoplasms of hypopharynx - Malignant neoplasms of nasopharynx - Malignant neoplasms of oropharynx

Cemiplimab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion	Therapeutic equivalent to pembrolizumab for - Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for - Adenocarcinoma of stomach - Other specified malignant neoplasms of bronchus or lung

Chlorambucil

Section	Indications
Cytotoxic medicines Oral > Solid: 2 mg tablet	- Unspecified malignant neoplasms of ill-defined or unspecified sites - Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Cisplatin

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
- Parenteral > General injections > IV: 10 mg per 10 mL; 20 mg per 20 mL; 50 mg per 50 mL; 100 mg per 100 mL
- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Germ cell tumour of testis

Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of cervix uteri

Malignant neoplasms of hypopharynx

Malignant neoplasms of oropharynx

Malignant neoplasms of nasopharynx

Cladribine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

Indications

Langerhans cell histiocytosis

Cobimetinib

Section

Targeted therapies

Indications

Therapeutic equivalent to trametinib for

Other specified melanoma of skin

Crizotinib

Section

Targeted therapies

- Oral > Solid: 200 mg; 250 mg
- Oral > Solid > capsule: 200 mg; 250 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Anaplastic large cell lymphoma, ALK-positive

Cyclophosphamide

Section

Cytotoxic medicines

- Oral > Solid: 25 mg tablet
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid > dosage form: 25 mg; 50 mg

Indications

- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Malignant neoplasms of breast
- Diffuse large B-cell lymphoma, not otherwise specified
- Chronic lymphocytic leukaemia or small lymphocytic lymphoma
- Plasma cell myeloma
- Other specified malignant neoplasms of breast
- Follicular lymphoma
- Burkitt lymphoma including Burkitt leukaemia
- Ewing sarcoma of bone and articular cartilage of unspecified sites
- Malignant trophoblastic neoplasms of placenta
- Lymphoid leukaemia, not elsewhere classified
- Rhabdomyosarcoma primary site
- Hodgkin lymphoma
- Other specified gliomas of brain
- Malignant neoplasms of kidney, except renal pelvis
- Anaplastic large cell lymphoma, ALK-negative
- Anaplastic large cell lymphoma, ALK-positive

Cytarabine

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

Indications

- Unspecified malignant neoplasms of ill-defined or unspecified sites
- Acute myeloid leukaemia with recurrent genetic abnormalities
- Burkitt lymphoma including Burkitt leukaemia
- Lymphoid leukaemia, not elsewhere classified
- Myeloid leukaemia
- Anaplastic large cell lymphoma, ALK-negative
- Anaplastic large cell lymphoma, ALK-positive
- Langerhans cell histiocytosis

Dabrafenib

Section

Targeted therapies

- Oral > Solid: 50 mg; 75 mg

Indications

Other specified melanoma of skin

Dacarbazine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

Indications

Hodgkin lymphoma

Dactinomycin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Malignant trophoblastic neoplasms of placenta

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Ewing sarcoma of bone and articular cartilage of unspecified sites

Daratumumab

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

Indications

Plasma cell myeloma

Darbepoetin alfa

Section

Supportive medicines

Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Drug-induced aplastic anaemia

Dasatinib

Section

Targeted therapies

- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

Indications

Chronic myeloid leukaemia, not elsewhere classified

Daunorubicin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Dexamethasone

Section

Hormones and antihormones

- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
- Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 4 mg (as dexamethasone base)

Indications

Anaplastic large cell lymphoma, ALK-negative

Lymphoid leukaemia, not elsewhere classified

Plasma cell myeloma

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-positive

Docetaxel

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Malignant neoplasms of prostate

Unspecified malignant neoplasms of ill-defined or unspecified sites

Dostarlimab

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion

Indications

Other specified malignant neoplasms of corpus uteri

Doxorubicin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride) ◦ Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)	Unspecified malignant neoplasms of ill-defined or unspecified sites Rhabdomyosarcoma primary site Follicular lymphoma Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Diffuse large B-cell lymphoma, not otherwise specified Hodgkin lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Lymphoid leukaemia, not elsewhere classified Other specified malignant neoplasms of breast Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Kaposi sarcoma of unspecified primary site

Doxorubicin (as pegylated liposomal)

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)	Kaposi sarcoma of unspecified primary site

Durvalumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion	Hepatocellular carcinoma of liver Malignant neoplasms of biliary tract, distal bile duct Malignant neoplasm of intrahepatic bile ducts Malignant neoplasms of gallbladder Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of proximal biliary tract, cystic duct

Encorafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to [dabrafenib](#) for

Other specified melanoma of skin

Enzalutamide

Section

Hormones and antihormones

- Oral > Solid: 40 mg

Indications

Therapeutic equivalent to [abiraterone](#) for

Malignant neoplasms of prostate

Malignant neoplasms of prostate

Epoetin alfa

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for

Drug-induced aplastic anaemia

Epoetin beta

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for

Drug-induced aplastic anaemia

Erlotinib

Section

Targeted therapies

- Oral > Solid: 100 mg; 150 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Erythropoiesis-stimulating agents

Section

Supportive medicines

- Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)

Indications

Drug-induced aplastic anaemia

Etoposide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule ◦ Oral > Solid: 100 mg capsule ◦ Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate) ◦ Oral > Solid: 100 mg capsule; 50 mg capsule	Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive

Everolimus

Section	Indications
Targeted therapies ◦ Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg ◦ Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg	Other specified gliomas of brain

Filgrastim

Section	Indications
Immunomodulators ◦ Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial	Acquired neutropaenia

Fludarabine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection ◦ Oral > Solid: 10 mg tablet (fludarabine phosphate)	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fluorouracil

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule ◦ Parenteral > General injections > IV: 50 mg per mL in vial	Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of nasopharynx Malignant neoplasm metastasis in large intestine Malignant neoplasms of breast Malignant neoplasms of rectum Malignant neoplasms of colon

Flutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate

Fulvestrant

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > IV: 250 mg per 5 mL	Malignant neoplasms of breast

Gefitinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

Gemcitabine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection	Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung

Goserelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [leuprorelin](#) for

Malignant neoplasms of breast

Therapeutic equivalent to [leuprorelin](#) for

Malignant neoplasms of prostate

Hydrocortisone

Section

Hormones and antihormones

- Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)

Indications

Lymphoid leukaemia, not elsewhere classified

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Hydroxycarbamide (hydroxyurea)

Section

Cytotoxic medicines

- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg

Indications

Squamous cell carcinoma of oropharynx

Chronic myeloid leukaemia, not elsewhere classified

Ibrutinib

Section

Targeted therapies

- Oral > Solid: 140 mg

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Ifosfamide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection ◦ Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection	Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive

Imatinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 100 mg; 400 mg	B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1 Chronic myeloid leukaemia, not elsewhere classified Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Ipilimumab

Section	Indications
Immunomodulators ◦ Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion	Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Melanoma of skin Other specified malignant neoplasms of bronchus or lung

Irinotecan

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Lenalidomide

Section

Immunomodulators

- Oral > Solid: 25 mg

Indications

Plasma cell myeloma

Lenvatinib

Section

Targeted therapies

- Oral > Solid > capsule: 4 mg; 10 mg

Indications

Renal cell carcinoma of kidney, except renal pelvis

Leuprorelin

Section

Hormones and antihormones

- Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

Lisocabtagene maraleucel

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to axicabtagene ciloleucel for

Diffuse large B-cell lymphomas

Melphalan

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg

Indications

Plasma cell myeloma

Mercaptopurine

Section

Cytotoxic medicines

- Oral > Solid: 50 mg tablet
- Oral > Liquid: 20 mg per mL

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Langerhans cell histiocytosis

Mesna

Section

Supportive medicines

- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
- Oral > Solid > tablet: 400 mg; 600 mg
- Oral > Other: 600 mg
- Oral > Solid > tablet: 400 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Osteosarcoma of bone and articular cartilage of other specified sites

Burkitt lymphoma including Burkitt leukaemia

Ewing sarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Methotrexate

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
- Oral > Solid: 2.5 mg (as sodium salt)
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

Malignant trophoblastic neoplasms of placenta

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Methylprednisolone

Section

Hormones and antihormones

- Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)
- Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection

Indications

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Nilotinib

Section

Targeted therapies

- Oral > Solid > capsule: 150 mg; 200 mg

Indications

Chronic myeloid leukaemia, not elsewhere classified

Nilutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [bicalutamide](#) for

Malignant neoplasms of prostate

Nivolumab

Section

Immunomodulators

- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for

Melanoma of skin

Melanoma of skin

Renal cell carcinoma of kidney, except renal pelvis

Other specified malignant neoplasms of bronchus or lung

Squamous cell carcinoma of oesophagus

Adenocarcinoma of oesophagogastric junction

Adenocarcinoma of stomach

Osimertinib

Section

Targeted therapies

- Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

Indications

Other specified malignant neoplasms of bronchus or lung

Oxaliplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial	Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon

Paclitaxel

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 6 mg per mL	Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri

Palbociclib

Section	Indications
Targeted therapies Oral > Solid: 75 mg; 100 mg; 125 mg	Other specified malignant neoplasms of breast

Panitumumab

Section	Indications
Targeted therapies Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial	Other specified malignant neoplasms of large intestine

Pegaspargase

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection	Lymphoid leukaemia, not elsewhere classified

Pegfilgrastim

Section

Immunomodulators

- Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

Indications

Acquired neutropaenia

Pembrolizumab

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion

Indications

Melanoma of skin

Other specified malignant neoplasms of large intestine

Malignant neoplasms of cervix uteri

Other specified malignant neoplasms of bronchus or lung

Adenocarcinoma of stomach

Malignant neoplasms of oesophagogastric junction

Squamous cell carcinoma of hypopharynx and variants

Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx

Squamous cell carcinoma of oropharynx

Squamous cell carcinoma of nasopharynx

Therapeutic equivalent to nivolumab for

Melanoma of skin

Renal cell carcinoma of kidney, except renal pelvis

Carcinoma of breast, specialised type

Squamous cell carcinoma of oesophagus

Pertuzumab

Section

Targeted therapies

- Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution

Indications

Carcinoma of breast, specialised type

Prednisolone

Section	Indications
Hormones and antihormones ◦ Oral > Liquid: 5 mg per mL ◦ Oral > Solid: 5 mg; 25 mg	Unspecified malignant neoplasms of ill-defined or unspecified sites Follicular lymphoma Lymphoid leukaemia, not elsewhere classified Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Hodgkin lymphoma Plasma cell myeloma Malignant neoplasms of prostate Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis

Prednisone

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [prednisolone](#) for

Follicular lymphoma

Therapeutic equivalent to [prednisolone](#) for

Lymphoid leukaemia, not elsewhere classified

Therapeutic equivalent to [prednisolone](#) for

Diffuse large B-cell lymphoma, not otherwise specified

Therapeutic equivalent to [prednisolone](#) for

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to [prednisolone](#) for

Hodgkin lymphoma

Therapeutic equivalent to [prednisolone](#) for

Plasma cell myeloma

Therapeutic equivalent to [prednisolone](#) for

Malignant neoplasms of prostate

Therapeutic equivalent to [prednisolone](#) for

Anaplastic large cell lymphoma, ALK-negative

Therapeutic equivalent to [prednisolone](#) for

Anaplastic large cell lymphoma, ALK-positive

Therapeutic equivalent to [prednisolone](#) for

Langerhans cell histiocytosis

Procarbazine

Section

Cytotoxic medicines

- Oral > Solid: 50 mg (as hydrochloride)
- Oral > Solid > capsule: 50 mg (as hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hodgkin lymphoma

Rasburicase

Section

Supportive medicines

- Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution

Indications

Tumour lysis syndrome

Realgar-indigo naturalis formulation

Section

Cytotoxic medicines

- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Ribociclib

Section

Targeted therapies

Indications

Therapeutic equivalent to **palbociclib** for

Other specified malignant neoplasms of breast

Rituximab

Section

Targeted therapies

- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Indications

Follicular lymphoma

Diffuse large B-cell lymphoma, not otherwise specified

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Burkitt lymphoma including Burkitt leukaemia

Tamoxifen

Section

Hormones and antihormones

- Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Temozolomide

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection
- Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg

Indications

Ewing sarcoma of bone and articular cartilage of unspecified sites

Other specified gliomas of brain

Unspecified malignant neoplasms of ill-defined or unspecified sites

Neuroblastoma, NOS

Thalidomide

Section

Immunomodulators

- Oral > Solid: 50 mg

Indications

Plasma cell myeloma

Tioguanine

Section

Cytotoxic medicines

- Oral > Solid: 40 mg

Indications

Lymphoid leukaemia, not elsewhere classified

Tisagenlecleucel

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to [axicabtagene ciloleucel](#) for

Diffuse large B-cell lymphomas

Tislelizumab

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 10 mL
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

Indications

Malignant neoplasms of urinary tract

Hodgkin lymphoma

Other specified malignant neoplasms of bronchus or lung

Squamous cell carcinoma of oesophagus

Toripalimab

Section

Immunomodulators

- Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

Malignant neoplasms of nasopharynx

Squamous cell carcinoma of oesophagus

Trametinib

Section

Targeted therapies

- Oral > Solid: 0.5 mg; 2 mg

Indications

Other specified melanoma of skin

Trastuzumab

Section

Targeted therapies

- Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

Trastuzumab emtansine

Section

Targeted therapies

- Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

Tremelimumab

Section

Immunomodulators

- Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion

Indications

Hepatocellular carcinoma of liver

Other specified malignant neoplasms of bronchus or lung

Triptorelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to leuporelin for

Malignant neoplasms of breast

Therapeutic equivalent to leuporelin for

Malignant neoplasms of prostate

Vemurafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to dabrafenib for

Other specified melanoma of skin

Vinblastine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Hodgkin lymphoma

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Kaposi sarcoma of unspecified primary site

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Vincristine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate) ◦ Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Follicular lymphoma Malignant trophoblastic neoplasms of placenta Diffuse large B-cell lymphoma, not otherwise specified Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis Lymphoid leukaemia, not elsewhere classified Retinoblastoma Langerhans cell histiocytosis

Vinorelbine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial ◦ Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial ◦ Oral > Solid > capsule: 20 mg; 30 mg; 80 mg	Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast Rhabdomyosarcoma primary site

Zanubrutinib

Section	Indications
Targeted therapies ◦ Oral > Solid: 80 mg ◦ Oral > Solid > capsule: 80 mg	Mantle cell lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to ibrutinib for Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Zoledronic acid

Section

Supportive medicines

- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

Malignant neoplasm metastasis in bone or bone marrow